Literature DB >> 35747709

Liver function monitoring in Fontan-procedure patients: audit of current practice across South Wales.

Elliott J Carande1, Gergely Szantho2.   

Abstract

The Fontan procedure provides a palliative surgical repair for complex congenital heart disease, but it is associated with many long-term problems, including liver cirrhosis, and hepatocellular carcinoma. The current suggestion from international guidance is that end-organ surveillance should be carried out, with a particular focus on regular blood tests and imaging for liver function. In this study, retrospective analysis was performed on adult patients who had previously had a Fontan operation performed to determine the regularity of end-organ surveillance in regards to their liver function covering the three calendar years from 2016 to 2018, and the first six months of 2019. Eighty-six patients were identified in South Wales monitored by the adult congenital heart disease unit. We found that the number of investigations performed in the first six months of 2019 was comparable to other calendar years in their entirety. Liver function tests had been performed in 57% of patients throughout 2018, with only 8% having had an alpha-fetoprotein taken, and only 9% having had imaging of the liver performed. Over the course of their lifetime, 97% of patients had had a liver function blood test performed at some point, with 17% having had an alpha-fetoprotein taken, and 49% having their liver imaged. In conclusion, end-organ surveillance is an important follow-up for patients with a Fontan circulation, with guidelines proposing yearly blood test and imaging investigations. This study shows the opportunities to improve surveillance in this group of patients to highlight the development of liver cirrhosis, and/or hepatocellular carcinoma.
Copyright © 2021 Medinews (Cardiology) Limited.

Entities:  

Keywords:  Fontan procedure; congenital heart defects; healthcare quality assurance; hepatocellular carcinoma; liver disease

Year:  2021        PMID: 35747709      PMCID: PMC8988802          DOI: 10.5837/bjc.2021.029

Source DB:  PubMed          Journal:  Br J Cardiol        ISSN: 0969-6113


  14 in total

Review 1.  The Fontan circulation.

Authors:  Marc Gewillig
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

2.  Successful use of the total artificial heart in the failing Fontan circulation.

Authors:  Joseph W Rossano; David J Goldberg; Stephanie Fuller; Chitra Ravishankar; Lisa M Montenegro; J William Gaynor
Journal:  Ann Thorac Surg       Date:  2014-04       Impact factor: 4.330

3.  Intermediate-term outcomes after combined heart-liver transplantation in children with a univentricular heart.

Authors:  Seth A Hollander; Olaf Reinhartz; Katsuhide Maeda; Melissa Hurwitz; David N Rosenthal; Daniel Bernstein
Journal:  J Heart Lung Transplant       Date:  2013-03       Impact factor: 10.247

4.  The Fontan procedure: anatomy, complications, and manifestations of failure.

Authors:  Tyler B Fredenburg; Tiffanie R Johnson; Mervyn D Cohen
Journal:  Radiographics       Date:  2011 Mar-Apr       Impact factor: 5.333

5.  Progression of liver pathology in patients undergoing the Fontan procedure: Chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma.

Authors:  Amir A Ghaferi; Grover M Hutchins
Journal:  J Thorac Cardiovasc Surg       Date:  2005-06       Impact factor: 5.209

6.  Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association.

Authors:  Jack Rychik; Andrew M Atz; David S Celermajer; Barbara J Deal; Michael A Gatzoulis; Marc H Gewillig; Tain-Yen Hsia; Daphne T Hsu; Adrienne H Kovacs; Brian W McCrindle; Jane W Newburger; Nancy A Pike; Mark Rodefeld; David N Rosenthal; Kurt R Schumacher; Bradley S Marino; Karen Stout; Gruschen Veldtman; Adel K Younoszai; Yves d'Udekem
Journal:  Circulation       Date:  2019-07-01       Impact factor: 29.690

7.  Liver cirrhosis in Fontan patients does not affect 1-year post-heart transplant mortality or markers of liver function.

Authors:  Kathleen E Simpson; Amir Esmaeeli; Geetika Khanna; Francis White; Yumirle Turnmelle; Pirooz Eghtesady; Umar Boston; Charles E Canter
Journal:  J Heart Lung Transplant       Date:  2013-10-25       Impact factor: 10.247

Review 8.  The Relentless Effects of the Fontan Paradox.

Authors:  Jack Rychik
Journal:  Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu       Date:  2016

9.  The clinical spectrum of Fontan-associated liver disease: results from a prospective multimodality screening cohort.

Authors:  Isabelle D Munsterman; Anthonie L Duijnhouwer; Timothy J Kendall; Carolien M Bronkhorst; Maxime Ronot; Morgane van Wettere; Arie P J van Dijk; Joost P H Drenth; Eric T T L Tjwa
Journal:  Eur Heart J       Date:  2019-04-01       Impact factor: 29.983

10.  Fontan-Associated Liver Disease: Spectrum of Disease in Children and Adolescents.

Authors:  Steven L Rathgeber; Orlee R Guttman; Anna F Lee; Christine Voss; Nicole M Hemphill; Richard A Schreiber; Kevin C Harris
Journal:  J Am Heart Assoc       Date:  2020-01-04       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.